

RITUXAN(R) Vials (500 mg/50 ml)Version
1.4Revision Date:
04-26-2021Date of last issue: 02-10-2020
Date of first issue: 06-10-2017**SECTION 1. IDENTIFICATION**

Product name : RITUXAN(R) Vials (500 mg/50 ml)

Product code : 00010063481

Manufacturer or supplier's details

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way
South San Francisco, CA 94080
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

Emergency telephone : US Chemtrec phone (800)-424-9300
number**Recommended use of the chemical and restrictions on use**

Recommended use : Formulated pharmaceutical active substance

Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Not a hazardous substance or mixture.

GHS label elements

Not a hazardous substance or mixture.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Substance

Substance name : MABTHERA 1,0% aqueous solution of Rituximab with excipients

CAS-No. : Not Assigned

Components

Chemical name	CAS-No.	Concentration (% w/w)
Rituximab	174722-31-7	1.0
Sodium chloride (NaCl)	7647-14-5	0.9
Sodium citrate	6132-04-3	0.74
Sorbitan, mono-(9Z)-9-	9005-65-6	0.07

RITUXAN(R) Vials (500 mg/50 ml)

Version 1.4 Revision Date: 04-26-2021 Date of last issue: 02-10-2020
 Date of first issue: 06-10-2017

octadecenoate, poly(oxy-1,2-ethanediyl) derivs.		
Water	7732-18-5	> 97.0

SECTION 4. FIRST AID MEASURES

- General advice : Do not leave the victim unattended.

- If inhaled : Move to fresh air.
 If unconscious, place in recovery position and seek medical advice.
 If symptoms persist, call a physician.

- In case of skin contact : If on skin, rinse well with water.

- In case of eye contact : Immediately flush eye(s) with plenty of water.
 Remove contact lenses.
 Protect unharmed eye.
 If eye irritation persists, consult a specialist.

- If swallowed : Keep respiratory tract clear.
 Do not give milk or alcoholic beverages.
 Never give anything by mouth to an unconscious person.
 If symptoms persist, call a physician.
 Rinse mouth with water.

- Most important symptoms and effects, both acute and delayed : None known.

- Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

- Specific hazards during fire fighting : No information available.

- Hazardous combustion products : In case of fire hazardous decomposition products may be produced such as:
 Carbon oxides
 Nitrogen oxides (NOx)

- Further information : Standard procedure for chemical fires.
 Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

RITUXAN(R) Vials (500 mg/50 ml)

Version
1.4

Revision Date:
04-26-2021

Date of last issue: 02-10-2020
Date of first issue: 06-10-2017

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Refer to protective measures listed in sections 7 and 8.
- Environmental precautions : Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece).
Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

- Advice on protection against fire and explosion : Normal measures for preventive fire protection.
- Advice on safe handling : For personal protection see section 8.
Smoking, eating and drinking should be prohibited in the application area.
- Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.
- Further information on storage conditions : See label, package insert or internal guidelines
- Materials to avoid : No materials to be especially mentioned.
- Storage temperature : Protected from heat and light
- Further information on storage stability : No decomposition if stored and applied as directed.
- Packaging material : Suitable material: Stainless steel, glass, Vials

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Rituximab	174722-31-7	IOEL	0.04 mg/m ³	Roche Industrial Hygiene Committee (RIHC)

Engineering measures : No data available

Personal protective equipment

Respiratory protection : No personal respiratory protective equipment normally

SAFETY DATA SHEET

RITUXAN(R) Vials (500 mg/50 ml)

Version
1.4

Revision Date:
04-26-2021

Date of last issue: 02-10-2020
Date of first issue: 06-10-2017

required.

Hand protection

In case of contact through splashing:
Material : Nitrile rubber
Break through time : > 30 min
Glove thickness : > 0.11 mm

In case of full contact:
Material : butyl-rubber
Break through time : > 480 min
Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact.
Replace torn or punctured gloves promptly.
Eye protection : Safety glasses
Skin and body protection : Protective suit
Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution, Clear liquid, Sterile liquid

Color : colorless

Odor : No data available

Odor Threshold : No data available

pH : 6.5

Melting point/range : No data available

Boiling point/boiling range : No data available

Evaporation rate : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

RITUXAN(R) Vials (500 mg/50 ml)

Version 1.4	Revision Date: 04-26-2021	Date of last issue: 02-10-2020 Date of first issue: 06-10-2017
----------------	------------------------------	---

Relative density	:	No data available
Density	:	1,012 g/cm ³
Solubility(ies)		
Water solubility	:	completely miscible
Solubility in other solvents	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	No dangerous reaction known under conditions of normal use.
Chemical stability	:	Stable under normal conditions. Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created
Possibility of hazardous reactions	:	Stable under recommended storage conditions. No hazards to be specially mentioned.
Incompatible materials	:	No data available
Hazardous decomposition products	:	No data available

SECTION 11. TOXICOLOGICAL INFORMATION
Acute toxicity

Not classified based on available information.

Components:
Rituximab:

Acute oral toxicity	:	Remarks: Not bioavailable by oral administration
Acute toxicity (other routes of administration)	:	Maximum tolerated dose (Mouse): > 100 mg/kg Application Route: i.p.

RITUXAN(R) Vials (500 mg/50 ml)

Version
1.4

Revision Date:
04-26-2021

Date of last issue: 02-10-2020
Date of first issue: 06-10-2017

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Aspiration toxicity

Not classified based on available information.

Further information

Components:

Rituximab:

Remarks : Globular proteins are generally well biodegradable

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

Components:

Rituximab:

RITUXAN(R) Vials (500 mg/50 ml)

Version
1.4

Revision Date:
04-26-2021

Date of last issue: 02-10-2020
Date of first issue: 06-10-2017

Biodegradability : Result: Globular proteins are generally well biodegradable

Bioaccumulative potential

Components:

Rituximab:

Partition coefficient: n-octanol/water : Remarks: No data available

Mobility in soil

No data available

Other adverse effects

Product:

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82
Protection of Stratospheric Ozone - CAA Section 602 Class I
Substances
Remarks: This product neither contains, nor was
manufactured with a Class I or Class II ODS as defined by the
U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A +
B).

Components:

Rituximab:

Additional ecological information : Monoclonal antibodies are proteins with highly specific affinity
to a certain antigen; therefore, no appreciable ecotoxic
potential is to be expected

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Can be disposed as waste water, when in compliance with
local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste
handling site for recycling or disposal.
Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

RITUXAN(R) Vials (500 mg/50 ml)Version
1.4Revision Date:
04-26-2021Date of last issue: 02-10-2020
Date of first issue: 06-10-2017

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

Domestic regulation**49 CFR**

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : No SARA Hazards**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.**Clean Air Act**

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCOMI Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations**Massachusetts Right To Know**

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know

Water

7732-18-5

Maine Chemicals of High Concern

Product does not contain any listed chemicals

RITUXAN(R) Vials (500 mg/50 ml)

Version
1.4

Revision Date:
04-26-2021

Date of last issue: 02-10-2020
Date of first issue: 06-10-2017

Vermont Chemicals of High Concern

Product does not contain any listed chemicals

Washington Chemicals of High Concern

Product does not contain any listed chemicals

The ingredients of this product are reported in the following inventories:

- AIC : Not in compliance with the inventory
- DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.


Rituximab
- NZIoC : On the inventory, or in compliance with the inventory
- ENCS : Not in compliance with the inventory
- ISHL : Not in compliance with the inventory
- KECI : Not in compliance with the inventory
- PICCS : Not in compliance with the inventory
- IECSC : Not in compliance with the inventory
- TCSI : Not in compliance with the inventory
- TSCA : Product contains substance(s) not listed on TSCA inventory.

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION

RITUXAN(R) Vials (500 mg/50 ml)Version
1.4Revision Date:
04-26-2021Date of last issue: 02-10-2020
Date of first issue: 06-10-2017**NFPA 704:****HMIS® IV:**

HEALTH	/	0
FLAMMABILITY		0
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AICC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

SAFETY DATA SHEET

RITUXAN(R) Vials (500 mg/50 ml)

Version
1.4

Revision Date:
04-26-2021

Date of last issue: 02-10-2020
Date of first issue: 06-10-2017

Revision Date : 04-26-2021

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 2004